Immunovia, Inc. is excited to introduce the IMMray® PanCan-d test, a microarray which measures 8 biomarkers plus CA19-9 to detect pancreatic ductal adenocarcinoma (PDAC) in serum. In a recent blind validation study, the IMMray PanCan-d test identified Stage I & II PDAC (n=56) vs high-risk individual controls (enrolled in a familial/hereditary pancreatic cancer surveillance program, n=203) with 98% specificity and 85% sensitivity. Across all PDAC stages (n=167) vs high-risk controls (n=203), the sensitivity increased to 87% with 98% specificity. The NPV was 0.995 (assumes 3% prevalence).
Brands: https://drive.google.com/file/d/1Pj4KpVDjN1P1oRkAHCwPX4oXeqw7id-A/view?usp=sharing
Press Releases
Products